Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PersAFOne III: Feasibility Study of the FARAPULSE Pulsed Field Ablation System Plus - PersAF in the Treatment of Persistent Atrial Fibrillation

NCT05272852 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT05272852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05272852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PersAFOne III: Feasibility Study of the FARAPULSE Pulsed Field Ablation System Plus - PersAF in the Treatment of Persistent Atrial Fibrillation
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Completed
Start date
February 3, 2022
Completion date
February 9, 2024
Enrollment
80 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

persistent atrial fibrillation